Cognitive enhancement therapy: An update;Traitements pharmacologiques des troubles cognitifs : Pistes actuelles

Therapie

Volumn 55, Issue 4, 2000, Pages 507-512

  Lestage, P ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Ageing; Cognition; Pharmacology

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; 4 AMINOPYRIDINE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMIRIDINE; ANIRACETAM; ARECOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FASORACETAM; HUPERZINE B; ICOPEZIL; LINOPIRDINE; MEMARON; METRIFONATE; MUSCARINIC AGENT; NEBRACETAM; NEFIRACETAM; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; OXIRACETAM; OXOTREMORINE; PHYSOSTIGMINE; PILOCARPINE; PIRACETAM; PRAMIRACETAM; QUILOSTIGMINE; RIVASTIGMINE; SABELUZOLE; SYNAPTON; TACRINE; UNCLASSIFIED DRUG;

AGING; AMNESIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DRUG EFFICACY; HUMAN; NEUROMODULATION; NEUROPHARMACOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMALS; CHOLINERGIC AGENTS; COGNITION DISORDERS; HUMANS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS;

EID: 0033692520     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Memoires et demences
2. Clonidine impairs sustained attention and memory in Alzheimer's disease
3. The α2 agonist, clonidine, improves spatial working memory performance in Parkinson's disease
4. Definition, course, and outcome of mild cognitive impairment
5. Alzheimer's disease: A disorder of cortical cholinergic innervation
6. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
7. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
8. A randomized controlled trial of linopiridine in the treatment of Alzheimer's disease
9. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors
10. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons, I: Pharmacological and functional evidence for distinct structural subtypes
11. Alzheimer's disease, attention, and the cholinergic system
12. Smoking, nicotine and human performance
13. Glutamate, learning and dementia-selection of evidence
14. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease.Investigative and therapeutic perspectives
15. Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine
16. Memantine in the treatment of mild to moderate dementia syndrome
17. Les mecanismes de la memoire
18. Aniracetam an overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders
19. Rogers Get al Psychological effects of a drug that facilitates brain AMPA receptors
20. S 18986-1, positive modulator of AMPA-type glutamate receptors, a novel cognitive enhancing agent
21. Serotonin, memory, and the aging brain
22. Distribution and cellular localization of mRNA Coding 5-HT(1a) receptor in the rat brain: Correlation with receptor binding
23. Stimulation of 5-HT(1a) receptors in fine dorsal hippocampus impairs acquisition and performance of a spatial task in a water maze
24. Neuropeptide modulation of learning and memory processes
25. Suppressive effect of a non-peptide prolyl endopeptidase (pep) inhibitor, Y-29794, on the amyloidogenesis of Senescence-accelerated mice (SAM)
26. Vers une pharmacologie de l'activite integree du cerveau: Tentative du concept nootrope en psychopharmacologie
27. Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women
28. Clinical trial: Of indomethacin in Alzheimer's disease
29. A radical hypothesis for neurodegeneration